Catalyst Dossier · compiled by CeliA 🧫

Oculis Holding AG (OCS)

Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-20

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Oculis Holding AG (OCS) is a small-cap (~$1.775B market cap, 49 employees) ophthalmic pharmaceutical company built around dexamethasone nanoparticle technology (OCS-01) and a broader pipeline spanning diabetic macular edema, dry eye disease, and optic neuritis. The stock carries an elevated dilution risk flag (23%) and just absorbed a Phase 3 negative readout in June 2026, with the next high-impact catalyst being a Phase 3 licaminlimab readout expected around December 2026.

The catalyst path

2026-08-20Earningsimp 5/10
2026-12-15 (est.)Phase 3 · licaminlimabimp 9/10

Pipeline

Asset	Phase	Indication
OCS-01	Phase 3	Inflammation Eye Pain
OCS-05 +SoC (corticosteroid) IV administration	Phase 2	Optic Neuritis
Dexamethasone ophthalmic suspension (OCS-01)	Phase 3	Diabetic Macular Edema
Dexamethasone nanoparticles eye drops	Phase 2	Diabetic Macular Edema
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL	Phase 2	Inflammation Corneal
licaminlimab	Phase 3	Dry Eye Disease
Privosegtor	Phase 3	Optic Neuritis

Price & technical context

3-month

-47.8%

6-month

-29.2%

12-month

-25.5%

52-wk range

$10.71–$32.65

vs 50-day MA

-33.0%

vs 200-day MA

-37.6%

Realized vol

71.1%

Max drawdown

-67.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OCS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.